Cloud-Clone pitches combined assay workflow for biomarker research

Cloud-Clone is promoting a two-step research workflow that uses multiplex bead-based assays for broad screening and ELISA for follow-up validation. The company says the approach can cut sample use, shorten timelines and improve confidence in protein-measurement studies across immunology, fibrosis, metabolism and cancer research.

Why it matters: - Cloud-Clone is positioning a combined assay strategy as a way to balance breadth and precision in protein research. - The workflow is aimed at labs studying complex networks where a single marker cannot explain disease biology. - The company says the approach can conserve scarce samples, reduce turnaround time and strengthen data credibility for journal submissions.

What happened: - Cloud-Clone Corp. outlined a two-step workflow that starts with multiplex bead-based screening and ends with ELISA validation. - The company framed the workflow as useful for researchers in immuno-inflammation, tumour microenvironment, bile-acid metabolism, fibrosis and gut microbiota studies. - The announcement was issued from Huston, Texas, on Oct. 13, 2026. - Cloud-Clone said the workflow combines its ELISA reagents with its IS135-series multiplex bead kits. - The company provided contact details and social links, including more information.

The details: - Multiplex bead-based assays are presented as the first-pass tool for high-throughput screening across pathways and marker panels. - ELISA is presented as the second-step tool for confirming 1 to 3 priority targets with triplicate or greater replication. - Cloud-Clone said both platforms use the sandwich immunoassay principle and internally sourced antigens and monoclonal antibody pairs. - The company said that consistency across reagent systems improves comparability between multiplex and ELISA results. - The company said its ELISA portfolio covers tens of thousands of analytes, including cytokines, metabolites, fibrosis markers and tumour biomarkers. - The company said its multiplex products are built from a library of more than 45,000 hybridoma clones for matched antibody pairs. - Cloud-Clone said multiplex assays can use 25-50 μL per well and run multiple analytes in a single assay. - The company said this makes multiplex testing suitable for limited samples such as mouse blood, biopsy supernatants, human aqueous humour and fetal-derived specimens. - Cloud-Clone said standalone ELISA can require 5-7 days for a 10-analyte panel and can consume too much sample for exploratory screening. - The company said multiplex screening can identify 3-5 statistically significant core markers for downstream validation. - Cloud-Clone said the combined workflow can reduce sample use by more than 60% in some study designs. - The company said testing 8 markers by ELISA alone can take more than a week, while an 8-plex bead screen can finish in one working day. - Cloud-Clone said follow-up ELISA on 2 targets can compress the full workflow to about two days. - The company said its product lines draw from more than 18,000 unique antigens and 27,000 distinct antibodies. - Cloud-Clone said its products follow three-stage closed-loop quality control, with validation by western blotting, immunohistochemistry and quantitative assay testing. - The company said support is available for multiplex instrument setup, ELISA incubation, sample dilution and statistical analysis, with responses within 24 hours.

Between the lines: - The pitch is less about replacing one assay with another and more about using each method where it performs best. - Multiplex screening narrows the field quickly, while ELISA is used to produce cleaner confirmation data for publication and follow-on experiments. - Cloud-Clone is also emphasizing platform compatibility, which matters because mixed-vendor reagent systems can create variability in assay behavior. - The company is targeting labs that need to stretch small sample volumes across many analytes without losing confidence in the final readout.

What's next: - Researchers using the workflow would start with multiplex screening, choose the strongest candidates and then run ELISA validation on independent plates. - Cloud-Clone is steering users to its broader reagent catalog and technical support as the combined workflow rolls out across disease-model and cohort studies. - The company says the model is suited to multi-pathway research and drug-development programs that need both speed and validation depth.

The bottom line: - Cloud-Clone is betting that the fastest route to credible biomarker data is not choosing between multiplex and ELISA, but using both in sequence.